Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
76%
Mantle Cell Lymphoma
72%
Lymphoma Patients
35%
MicroRNA
32%
Poor Outcome
31%
DNA Methylation (DNAm)
28%
Myelodysplastic Syndrome
28%
Epigenetic Modification
27%
Multiple Myeloma
27%
Lenalidomide
27%
Death-associated Protein Kinase 1 (DAPK1)
24%
T Cells
22%
Overall Survival
22%
Promoter Methylation
21%
Rituximab
20%
Methylation Status
19%
Tumor Protein p53 (TP53)
19%
Vitamin C
19%
Pyrosequencing
19%
DNA Methyltransferase Inhibitor
18%
5-azacytidine
18%
Myeloid Cancer
17%
5-aza-2′-deoxycytidine
17%
Tumor Cells
17%
MicroRNA Expression
17%
Hypermethylation
17%
Hypomethylating Agents
16%
Overexpression
16%
International Prognostic Index
16%
Histone Deacetylase Inhibitor (HDACi)
16%
B-cell Malignancies
16%
Methylation
16%
Independent Prognostic Factor
16%
Azacitidine
15%
Immunomodulatory Drugs (IMiDs)
15%
Response Predictors
15%
Idiopathic Cytopenia of Undetermined Significance
15%
Autoimmune Lymphoproliferative Syndrome
15%
Cytopenia
15%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Methylation
94%
DNA Methylation
67%
Myeloid
48%
Promoter Region
41%
T Cell
39%
MicroRNA
39%
Epigenetics
31%
Azacitidine
30%
Pyrosequencing
23%
Vitamin C
22%
Decitabine
18%
Tumor Suppressor Protein
17%
Allele
17%
Overall Survival
17%
Upregulation
16%
DNA Methyltransferase
16%
DAPK1
15%
Spliceosome
15%
Medicine and Dentistry
Mantle Cell Lymphoma
51%
Malignant Neoplasm
42%
Diseases
37%
microRNA
36%
Diffuse Large B-Cell Lymphoma
27%
Cytopenia
26%
Ascorbic Acid
22%
Diagnosis
22%
Rituximab
22%
Cancer
20%
Epigenetic Therapy
18%
DNA Methyltransferase Inhibitor
17%
Mantle Cell Lymphoma International Prognostic Index
17%
B Cell
16%
Neoplasm
15%
Janus Kinase
15%
Azacitidine
15%
Autoimmune Lymphoproliferative Syndrome
15%
Cutaneous T Cell Lymphoma
15%
